Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01970943 · ClinicalTrials.gov registry record · NA
Molecular and Functional PET-fMRI Measures of Analgesia in Migraine
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT01970943: Completed NA study, sponsored by Massachusetts General Hospital.
NCT01970943 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01970943, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
The placebo effect is a phenomenon that has experienced major advances of its understanding in the last decade. However, mechanisms of placebo analgesia in chronic pain patients have yet to be compared to healthy subjects. The investigators study aims to investigate the magnitude of placebo response and related opioid release in patients that suffer from episodic migraines as compared to healthy controls. In particular, the investigators are looking to map brain activity during placebo analgesia using modern brain imaging techniques such as functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET). The investigators hypothesis is that placebo response and the availability of opioid receptors is reduced in chronic migraine patients.
Interventions
- OTHER Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2012-09-01 |
| Est. Completion | 2017-10-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01970943
The ClinicalTrials.gov registry entry for NCT01970943 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Placebo is the first listed.
NCT01970943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01970943 about?
NCT01970943 is a clinical study titled "Molecular and Functional PET-fMRI Measures of Analgesia in Migraine". The placebo effect is a phenomenon that has experienced major advances of its understanding in the last decade. However, mechanisms of placebo analgesia in chronic pain patients have yet to be compared to healthy subjects. The investigators study aims to investigate the magnitude of placebo response...
What is the current status of trial NCT01970943?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2012-09-01. Estimated completion is 2017-10-30.
What interventions are being tested in trial NCT01970943?
The interventions under investigation include: Placebo (OTHER).
Who is sponsoring clinical trial NCT01970943?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.